ER-100 epigenetic therapy for glaucoma, open-angle

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Dec 2025: Trial registered, NCT07290244
  2. 2 Mar 2026: Trial started, NCT07290244

The trials

NCT07290244: Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

State
Under way
Phase
Phase 1
People
18 planned
Started
2 Mar 2026
Primary completion
May 2027
Arms
OAG - Low Dose ER-100 (2 x 10^11 vg/eye), OAG - High Dose ER-100 (6 x 10^11 vg/eye), NAION - Selected Dose ER-100
Results
None posted
  1. 18 Dec 2025: Trial registered
  2. 2 Mar 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.